Dengue, caused by infection of any of four dengue virus serotypes (DENV-1 to DENV-4), is a
mosquito-borne disease of major public health concern associated with significant morbidity …

Dengue is the world's most prevalent and important arboviral disease. More than 50% of the
world's population lives at daily risk of infection and it is estimated more than 95 million …

Background In light of the increasing rate of dengue infections throughout the world despite
vector-control measures, several dengue vaccine candidates are in development. Methods …

Background An estimated 100 million people have symptomatic dengue infection every
year. This is the first report of a phase 3 vaccine efficacy trial of a candidate dengue vaccine …

Dengue virus poses a major threat to global public health: two-thirds of the world's
population is now at risk from infection by this mosquito-borne virus. Dengue virus causes a …

Background Roughly half the world's population live in dengue-endemic countries, but no
vaccine is licensed. We investigated the efficacy of a recombinant, live, attenuated …

The first approved dengue vaccine has now been licensed in six countries. We propose that
this live attenuated vaccine acts like a silent natural infection in priming or boosting host …

This clinical review has been developed for The BMJ in collaboration with BMJ Best
Practice, based on a regularly updated web/mobile topic that supports evidence based …

Sanofi Pasteur has developed a recombinant, live-attenuated, tetravalent dengue vaccine
(CYD-TDV) that is in late-stage development. The present review summarizes the different …

Each novel vaccine candidate needs to be evaluated for safety, immunogenicity, and
protective efficacy in humans before it is licensed for use. After initial safety evaluation in …